Cingulate therapeutics headquarters
WebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva Cingulate Inc. Reports First Quarter 2024 Results and Provides Clinical and Business Update Announcement of First Subject Dosing for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Release™ … WebView Arthur Straughn's business profile as Co-founder Board of Directors at Cingulate Therapeutics. Find Arthur's email address, mobile number, work history, and more. Product About Create Free Account. Wrong ... Arthur Straughn's HQ phone number is +1 913-942-2300. Who are Arthur Straughn's colleagues? Arthur Straughn's colleagues are Lou Horn ...
Cingulate therapeutics headquarters
Did you know?
WebCingulate Inc. 1,061 followers. 2mo. Today we announce our Q3 2024 financial results and provided a clinical and business update, including updated study timelines for our lead … WebMar 30, 2024 · EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML: 10 Mar 2024: 10-K: Annual report which provides a comprehensive overview of the company for the past year
WebApr 10, 2024 · Analyst Forecast. According to 10 analysts, the average rating for CING stock is "Buy." The 12-month stock price forecast is $5.99, which is an increase of 508.12% from the latest price. WebJun 15, 2024 · Kansas City, KS – (June 15, 2024) – Cingulate Therapeutics, LLC, a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), today announced that it has moved the location of its Kansas City headquarters.
WebFind the latest Cingulate Inc. (CING) stock quote, history, news and other vital information to help you with your stock trading and investing. WebOct 13, 2024 · Founded in 2013, Cingulate is a clinical-stage biopharmaceutical company. The company uses its proprietary Precision Timed Release (PTR) drug delivery platform technology to treat patients with...
WebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being developed to serve the roughly $5 billion U.S. … 10 Mar 2024 Cingulate Inc. Reports Fourth Quarter and Full Year 2024 Financial … Pipeline Overview. Cingulate® completed a proof-of-concept trial in human subjects … Cingulate Inc. 1901 W 47th Place Kansas City, KS 66205 (913) 942-2300 … Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and … About Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage … Mr. Gallagher is a Co-Founder of Cingulate Therapeutics and serves as a member …
WebJun 24, 2024 · Virtual. We are pleased to invite you to a virtual call series highlighting the next generation of life sciences private companies from Monday, June 29 th – Thursday, July 2 nd, 2024. We will be hosting the companies for 35 minute presentations with time for Q&A over the four days. green card lottery 2022 linkWebMr. Peter Werth serves as Board Member at Cingulate Therapeutics. He is the Founder and also serves as Chief Executive Officer at Werth Ventures. He serves as Board Member at Alopexx Enterprises. He is the Owner & serves as the Chief Executive Officer & President at Chemwerth. He also served as a board member at InnoPharma. flow gmc of fayettevilleWebJun 15, 2024 · KANSAS CITY, Kan., June 15, 2024 /PRNewswire/ -- Cingulate Therapeutics, LLC, a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), today announced that it has moved the location of … flow gmc service winston salemWebDec 8, 2024 · KANSAS CITY, Kan., Dec. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (“Cingulate” or the “Company”), a clinical-stage biopharmaceutical company utilizing... flow gmc used trucksWebApr 3, 2024 · Cingulate Therapeutics's annual revenues are $10-$50 million (see exact revenue data) and has 10-100 employees. It is classified as operating in the Pharmaceutical & Medicine Manufacturing industry. Cingulate Therapeutics's Annual Report & Profile shows critical firmographic facts: What is the company's size? (Annual sales and … green card lottery 2015 results by countryWebCingulate Therapeutics Primary Sponsor contact: Holly Mitzel Cingulate Therapeutics 1901 W. 47th Place, Suite 310 Kansas City, KS 66205 E: [email protected] P: 913-942-2304 Secondary Sponsor contact: Matt Brams, MD Cingulate Therapeutics 1901 W. 47th Place, Suite 310 Kansas City, KS … flow g ng litexWebJul 11, 2024 · 11 Jul 2024 Cingulate CEO: $7.5M fundraising round will help drive pharma growth in KC. A former Marion Laboratories employee, Shane Schaffer’s goal from the … green card lottery 2018 results